Abstract
Lung involvement in primary Sjögren syndrome occurs in approximately 10-20% of patients. Tocilizumab, an anti-interleukin-6 receptor antibody, has demonstrated efficacy and safety in small series of systemic sclerosis, and systemic lupus erythematosus, but its effect on interstitial lung manifestations of connective tissue diseases is not well known. We report the use of tocilizumab in a refractory organising pneumonia associated with Sjögren's disease. Our observation suggests that tocilizumab could be an alternative therapeutic in refractory organising pneumonia.
2015 BMJ Publishing Group Ltd.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antirheumatic Agents / therapeutic use
-
Cryptogenic Organizing Pneumonia / complications*
-
Cryptogenic Organizing Pneumonia / diagnostic imaging
-
Cryptogenic Organizing Pneumonia / drug therapy*
-
Drug Therapy, Combination
-
Humans
-
Immunologic Factors / therapeutic use
-
Male
-
Middle Aged
-
Positron-Emission Tomography
-
Prednisolone / therapeutic use
-
Radiography
-
Receptors, Interleukin-6
-
Rituximab / therapeutic use
-
Sjogren's Syndrome / complications*
-
Sjogren's Syndrome / diagnostic imaging
-
Sjogren's Syndrome / drug therapy*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunologic Factors
-
Receptors, Interleukin-6
-
Rituximab
-
Prednisolone
-
tocilizumab